Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2016
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 04 May 2016 Status changed from recruiting to discontinued.
- 19 Jan 2015 Planned End Date changed from 1 Aug 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 19 Jan 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.